Monte Rosa Therapeutics, Inc. GLUE
Updated: 17 Jun 2026
No signal published yet
We already track Monte Rosa Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Monte Rosa Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Monte Rosa Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, Monte Rosa reported Q1 financial results, highlighting a cash position of $671 million following a $345 million equity raise in January. The company announced plans to initiate multiple Phase 2 trials in the second half of 2026, including studies for MRT-8102 in cardiovascular risk and MRT-2359 in prostate cancer.
What Firelda Watch includes for Monte Rosa Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Monte Rosa Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Monte Rosa Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more